Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | BAD | Q92934 | 1/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL751998 | 0.96 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTFFAR3LCKFYN | |
| Acetic Acid SCHEMBL27763922 | 0.93 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPTFFAR3LCKFYN | |
| Acetone SCHEMBL5003447 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTL3MBTL1HTTHSD17B1 | |
| Acetic Acid SCHEMBL9809831 | 0.87 | HSD17B1 (0.68) | SMN1; SMN2MAPTHSD17B1HSD17B10BCL2L1 | |
| Acetic Acid SCHEMBL15333210 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTHSD17B10RXRARXRB | |
| Biphenyl SCHEMBL538359 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTL3MBTL1HTTHSD17B10 | |
| Pyruvate SCHEMBL4627034 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPTL3MBTL1HTTHSD17B1 | |
| Biphenyl SCHEMBL15332958 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTL3MBTL1HTTHSD17B10 | |
| Biphenyl SCHEMBL29059196 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTL3MBTL1HTTHSD17B10 | |
| Benzidine SCHEMBL2963173 | 0.85 | TDP1 (0.61) | SMN1; SMN2MAPTL3MBTL1HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117046304-A | Acid-catalyzed cross-linked high-flux acid-resistant nanofiltration membrane and preparation method thereof | 宁波日新恒力科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| EP-0483261-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1992-05-06 | — | — | EP | claimed |
| WO-1991001328-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | claimed |
| US-4859667-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1989-08-22 | — | — | US | claimed |
| JP-5279425-A | — | — | None | — | — | JP | disclosed |
| CN-117881395-A | Compositions for delivery of mRNA | 翻译生物公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117225384-B | Composite material capable of efficiently adsorbing formaldehyde and noble metal as well as preparation method and application thereof | 天津得瑞丰凯新材料科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117225384-A | Composite material capable of efficiently adsorbing formaldehyde and noble metal as well as preparation method and application thereof | 天津得瑞丰凯新材料科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117046304-A | Acid-catalyzed cross-linked high-flux acid-resistant nanofiltration membrane and preparation method thereof | 宁波日新恒力科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-109777851-B | Method for improving penicillin biological fermentation yield | 华东理工大学 | 2022-08-23 | — | — | CN | disclosed |
| US-20210276960-A1 | INHIBITORS OF TISSUE TRANSGLUTAMINASE 2 (TG2) AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2021-09-09 | — | — | US | disclosed |
| US-9725602-B2 | Method for preparing an organic film at the surface of a solid support under non-electrochemical conditions, solid support thus obtained and preparation kit | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-08 | — | — | US | disclosed |
| EP-0529031-A1 | IMPROVED INHIBITORS OF THROMBIN | BIOGEN, INC. (US) | 1993-03-03 | — | — | EP | disclosed |
| WO-1992013952-A1 | IMPROVED INHIBITORS OF THROMBIN | BIOGEN, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0489070-A1 | NOVEL INHIBITORS OF THROMBIN. | BIOGEN INC (US) | 1992-06-10 | — | — | EP | disclosed |
| EP-0483261-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1992-05-06 | — | — | EP | disclosed |
| EP-0482069-A1 | COMBINATIONS AND METHODS FOR TREATING OR PREVENTING THROMBOTIC DISEASES | BIOGEN, INC. (US) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991002750-A1 | NOVEL INHIBITORS OF THROMBIN | BIOGEN, INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| WO-1991001328-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| WO-1991001142-A1 | COMBINATIONS AND METHODS FOR TREATING OR PREVENTING THROMBOTIC DISEASES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276960-A1 | INHIBITORS OF TISSUE TRANSGLUTAMINASE 2 (TG2) AND USES THEREOF | TGM2, TGM3, TGM6 | ESR1 4238/4885ESR2 2093/4885SMN1; SMN2 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.